Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Emergent BioSolutions
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
July 09, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
July 02, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
July 02, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
June 20, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day
June 06, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024
May 10, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Reports First Quarter 2024 Financial Results
May 01, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
May 01, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
May 01, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Announces Amendment to its Existing Credit Facility
April 30, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
April 22, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
March 28, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
March 25, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
March 06, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
February 29, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
February 21, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
BLCO
EBS
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
January 11, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
January 09, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
November 28, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
November 24, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
November 08, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
October 30, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
October 19, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
October 02, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
LQDA
Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
August 30, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Reports Financial Results for Second Quarter 2023
August 08, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
August 08, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
July 31, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
July 25, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
July 20, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.